IDYA
Price
$21.37
Change
-$0.92 (-4.13%)
Updated
Jun 27 closing price
Capitalization
1.87B
44 days until earnings call
IKT
Price
$1.62
Change
-$0.03 (-1.82%)
Updated
Jun 27 closing price
Capitalization
119.69M
Interact to see
Advertisement

IDYA vs IKT

Header iconIDYA vs IKT Comparison
Open Charts IDYA vs IKTBanner chart's image
IDEAYA Biosciences
Price$21.37
Change-$0.92 (-4.13%)
Volume$3.2M
Capitalization1.87B
Inhibikase Therapeutics
Price$1.62
Change-$0.03 (-1.82%)
Volume$7.07M
Capitalization119.69M
IDYA vs IKT Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. IKT commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and IKT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (IDYA: $21.37 vs. IKT: $1.62)
Brand notoriety: IDYA and IKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 248% vs. IKT: 2494%
Market capitalization -- IDYA: $1.87B vs. IKT: $119.69M
IDYA [@Biotechnology] is valued at $1.87B. IKT’s [@Biotechnology] market capitalization is $119.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileIKT’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • IKT’s FA Score: 1 green, 4 red.
According to our system of comparison, IKT is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while IKT’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 5 bearish.
  • IKT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both IDYA and IKT are a bad buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а -1.38% price change this week, while IKT (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.87B) has a higher market cap than IKT($120M). IDYA YTD gains are higher at: -16.848 vs. IKT (-50.154). IKT has higher annual earnings (EBITDA): -39.54M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. IKT (93.2M). IKT has less debt than IDYA: IKT (74.8K) vs IDYA (26M). IDYA has higher revenues than IKT: IDYA (7M) vs IKT (0).
IDYAIKTIDYA / IKT
Capitalization1.87B120M1,561%
EBITDA-356.46M-39.54M902%
Gain YTD-16.848-50.15434%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash693M93.2M744%
Total Debt26M74.8K34,759%
FUNDAMENTALS RATINGS
IDYA: Fundamental Ratings
IDYA
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
71
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IDYAIKT
RSI
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLRTX10.240.06
+0.59%
NYLI Winslow Large Cap Growth Class R2
CEVYX12.500.05
+0.40%
Columbia Global Value Inst3
HSSCX23.660.07
+0.30%
Emerald Finance & Bking Innovt Fd C
DVRUX17.130.05
+0.29%
UBS US Dividend Ruler P
CZMSX15.630.01
+0.06%
Multi-Manager Small Cap Eq Strat Inst

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-4.13%
IMNM - IDYA
61%
Loosely correlated
-0.23%
CGON - IDYA
60%
Loosely correlated
-0.46%
CRNX - IDYA
56%
Loosely correlated
-0.10%
DNLI - IDYA
56%
Loosely correlated
-2.69%
SYRE - IDYA
56%
Loosely correlated
-4.99%
More

IKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IKT has been loosely correlated with CRGX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if IKT jumps, then CRGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IKT
1D Price
Change %
IKT100%
-1.82%
CRGX - IKT
44%
Loosely correlated
-0.71%
IDYA - IKT
35%
Loosely correlated
-4.13%
ARWR - IKT
34%
Loosely correlated
+0.06%
TRDA - IKT
33%
Poorly correlated
-1.57%
SYRE - IKT
32%
Poorly correlated
-4.99%
More